Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Adaptive Biotechnologies

DB:1HM
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1HM
DB
$4B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The last earnings update was 41 days ago. More info.


Add to Portfolio Compare Print
  • Adaptive Biotechnologies has significant price volatility in the past 3 months.
1HM Share Price and Events
7 Day Returns
0.8%
DB:1HM
2.3%
Europe Life Sciences
-0.6%
DE Market
1 Year Returns
-
DB:1HM
24.4%
Europe Life Sciences
-20.9%
DE Market
1HM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Adaptive Biotechnologies (1HM) 0.8% 0.8% -6.9% - - -
Europe Life Sciences 2.3% -0.1% 5.1% 24.4% 77.9% 174.4%
DE Market -0.6% -16.6% -26% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • No trading data on 1HM.
  • No trading data on 1HM.
Price Volatility
Industry
5yr Volatility vs Market

1HM Value

 Is Adaptive Biotechnologies undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Adaptive Biotechnologies. This is due to cash flow or dividend data being unavailable. The share price is €24.4.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Adaptive Biotechnologies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Adaptive Biotechnologies's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:1HM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.01
NasdaqGS:ADPT Share Price ** NasdaqGS (2020-04-06) in USD $28.08
Europe Life Sciences Industry PE Ratio Median Figure of 18 Publicly-Listed Life Sciences Companies 49.09x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.45x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Adaptive Biotechnologies.

DB:1HM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ADPT Share Price ÷ EPS (both in USD)

= 28.08 ÷ -1.01

-27.92x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Adaptive Biotechnologies is loss making, we can't compare its value to the Europe Life Sciences industry average.
  • Adaptive Biotechnologies is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Adaptive Biotechnologies's expected growth come at a high price?
Raw Data
DB:1HM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -27.92x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
12.5%per year
Europe Life Sciences Industry PEG Ratio Median Figure of 15 Publicly-Listed Life Sciences Companies 2.25x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.16x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Adaptive Biotechnologies, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Adaptive Biotechnologies's assets?
Raw Data
DB:1HM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $4.56
NasdaqGS:ADPT Share Price * NasdaqGS (2020-04-06) in USD $28.08
Europe Life Sciences Industry PB Ratio Median Figure of 41 Publicly-Listed Life Sciences Companies 3.87x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:1HM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ADPT Share Price ÷ Book Value per Share (both in USD)

= 28.08 ÷ 4.56

6.16x

* Primary Listing of Adaptive Biotechnologies.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Adaptive Biotechnologies is overvalued based on assets compared to the Europe Life Sciences industry average.
X
Value checks
We assess Adaptive Biotechnologies's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Adaptive Biotechnologies has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

1HM Future Performance

 How is Adaptive Biotechnologies expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
12.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Adaptive Biotechnologies expected to grow at an attractive rate?
  • Unable to compare Adaptive Biotechnologies's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Adaptive Biotechnologies's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Adaptive Biotechnologies's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:1HM Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:1HM Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 12.5%
DB:1HM Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 26.4%
Europe Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 18.4%
Europe Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 7.9%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:1HM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:1HM Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 368 -35 1
2023-12-31 298 -74 1
2022-12-31 253 -97 -105 4
2021-12-31 188 -131 -130 5
2020-12-31 112 -115 -120 5
2020-04-07
DB:1HM Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 85 205 -70
2019-09-30 78 227 -62
2019-06-30 69 245 -56
2019-03-31 59 252 -53
2018-12-31 56 -32 -46
2017-12-31 38 -35 -43

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Adaptive Biotechnologies is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Adaptive Biotechnologies's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:1HM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Adaptive Biotechnologies Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1HM Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -0.24 -0.24 -0.24 1.00
2023-12-31 -0.53 -0.53 -0.53 1.00
2022-12-31 -0.80 -0.76 -0.84 3.00
2021-12-31 -1.01 -0.91 -1.14 4.00
2020-12-31 -0.95 -0.92 -0.99 4.00
2020-04-07
DB:1HM Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.01
2019-09-30 -1.51
2019-06-30 -4.34
2019-03-31 -4.12
2018-12-31 -3.67
2017-12-31 -3.50

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Adaptive Biotechnologies will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Adaptive Biotechnologies's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Adaptive Biotechnologies has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

1HM Past Performance

  How has Adaptive Biotechnologies performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Adaptive Biotechnologies's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Adaptive Biotechnologies does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Adaptive Biotechnologies's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Adaptive Biotechnologies's 1-year growth to the Europe Life Sciences industry average as it is not currently profitable.
Earnings and Revenue History
Adaptive Biotechnologies's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Adaptive Biotechnologies Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1HM Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 85.07 -69.57 68.79
2019-09-30 78.05 -62.13 62.52
2019-06-30 69.18 -56.47 55.72
2019-03-31 58.61 -52.60 50.13
2018-12-31 55.66 -46.35 44.90
2017-12-31 38.45 -42.70 32.71

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Adaptive Biotechnologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Adaptive Biotechnologies has efficiently used its assets last year compared to the Europe Life Sciences industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Adaptive Biotechnologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Adaptive Biotechnologies's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Adaptive Biotechnologies has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

1HM Health

 How is Adaptive Biotechnologies's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Adaptive Biotechnologies's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Adaptive Biotechnologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Adaptive Biotechnologies's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Adaptive Biotechnologies's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Adaptive Biotechnologies has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Adaptive Biotechnologies Company Filings, last reported 3 months ago.

DB:1HM Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 571.04 0.00 576.87
2019-09-30 585.93 0.00 573.43
2019-06-30 280.16 0.00 423.00
2019-03-31 288.09 0.00 440.43
2018-12-31 303.08 0.00 165.02
2017-12-31 337.06 0.00 192.15
  • Adaptive Biotechnologies has no debt.
  • Adaptive Biotechnologies has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Adaptive Biotechnologies has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Adaptive Biotechnologies has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -91.8% per year.
X
Financial health checks
We assess Adaptive Biotechnologies's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Adaptive Biotechnologies has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

1HM Dividends

 What is Adaptive Biotechnologies's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Adaptive Biotechnologies dividends. Estimated to be 0% next year.
If you bought €2,000 of Adaptive Biotechnologies shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Adaptive Biotechnologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Adaptive Biotechnologies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:1HM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 12 Stocks 0.7%
Germany Market Average Dividend Yield Market Cap Weighted Average of 315 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:1HM Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-04-07

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Adaptive Biotechnologies has not reported any payouts.
  • Unable to verify if Adaptive Biotechnologies's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Adaptive Biotechnologies's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Adaptive Biotechnologies has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Adaptive Biotechnologies's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Adaptive Biotechnologies's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Adaptive Biotechnologies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Adaptive Biotechnologies has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

1HM Management

 What is the CEO of Adaptive Biotechnologies's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chad Robins
COMPENSATION $2,470,231
AGE 44
TENURE AS CEO 10.6 years
CEO Bio

Mr. Chad M. Robins, M.B.A., co-founded Adaptive Biotechnologies Corporation in September 2009 and has served as its Chief Executive Officer and Director since incorporation. Prior to co-founding Adaptive Biotechnologies Corporation, Mr. Robins held numerous executive-level positions in medical technology, investment and real estate companies. He held a corporate finance position at Bank of America. He opened the West Coast office of Wasserstein Perella’s software and internet services group before moving to the operating side to run the West Coast office of a publicly traded online health insurance company, HealthAxis.com. Post Wharton, he served as Vice President of Operations for Pulte Homes (NYSE:PHM) and Chief Operating Officer for Connaught Real Estate Finance, an opportunistic hedge fund. He serves as a Member of Business Advisory Board at Zentalis Pharmaceuticals LLC. He serves as a Director of Pavia Systems, Inc. Mr. Robins holds an MBA from The Wharton School at the University of Pennsylvania and a BS in Managerial Economics from Cornell University.

CEO Compensation
  • Chad's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Chad's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Adaptive Biotechnologies management team in years:

5.2
Average Tenure
46
Average Age
  • The average tenure for the Adaptive Biotechnologies management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Chad Robins

TITLE
Co-Founder
COMPENSATION
$2M
AGE
44
TENURE
10.6 yrs

Harlan Robins

TITLE
Co-Founder & Chief Scientific Officer
COMPENSATION
$2M
AGE
45
TENURE
10.6 yrs

Lance Baldo

TITLE
Chief Medical Officer
COMPENSATION
$4M
AGE
46
TENURE
1 yrs

Julie Rubinstein

TITLE
President
COMPENSATION
$2M
AGE
47
TENURE
2.2 yrs

Christopher Carlson

TITLE

Chad Cohen

TITLE
Chief Financial Officer
AGE
44
TENURE
4.7 yrs

Nancy Hill

TITLE
Senior Vice President of Operations
AGE
55
TENURE
6.3 yrs

Sean Nolan

TITLE
Chief Technology Officer
AGE
49
TENURE
5.8 yrs

Stacy Taylor

TITLE
Senior VP & General Counsel
AGE
59

Francis Lo

TITLE
Chief People Officer
AGE
38
TENURE
1 yrs
Board of Directors Tenure

Average tenure and age of the Adaptive Biotechnologies board of directors in years:

1.1
Average Tenure
63
Average Age
  • The average tenure for the Adaptive Biotechnologies board of directors is less than 3 years, this suggests a new board.
Board of Directors

Chad Robins

TITLE
Co-Founder
COMPENSATION
$2M
AGE
44

Peter Neupert

TITLE
Lead Independent Director
COMPENSATION
$160K
AGE
63

Michelle Griffin

TITLE
Independent Director
COMPENSATION
$828K
AGE
53
TENURE
1.1 yrs

Andy Zoltners

TITLE
Independent Director
COMPENSATION
$89K
AGE
73
TENURE
10.3 yrs

Arnie Levine

TITLE
Member of Scientific Advisory Board
COMPENSATION
$69K
AGE
79
TENURE
0.9 yrs

Craig Weissman

TITLE
Member of Corporate Advisory Board

Graham Allen

TITLE
Member of Corporate Advisory Board

Matt Kahn

TITLE
Member of Corporate Advisory Board

Carol Gallagher

TITLE
Member of Corporate Advisory Board
AGE
54

H. Parker

TITLE
Member of Corporate Advisory Board
AGE
63
Who owns this company?
Recent Insider Trading
  • Adaptive Biotechnologies individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
30. Jan 20 Sell Viking Global Investors LP Company 28. Jan 20 28. Jan 20 -4,912,899 €22.69 €-111,466,166
29. Jan 20 Sell Andris Zoltners Individual 28. Jan 20 28. Jan 20 -245,000 €24.07 €-5,897,787
07. Jan 20 Buy Francis Lo Individual 01. Jul 19 01. Jul 19 2,500 €17.68 €44,190
02. Jul 19 Buy Viking Global Investors LP Company 01. Jul 19 01. Jul 19 173,010 €17.68 €3,058,125
03. Jul 19 Buy Chad Cohen Individual 01. Jul 19 01. Jul 19 1,000 €17.68 €17,676
03. Jul 19 Buy Nancy Hill Individual 01. Jul 19 01. Jul 19 11,200 €17.68 €197,971
X
Management checks
We assess Adaptive Biotechnologies's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Adaptive Biotechnologies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

1HM News

Simply Wall St News

1HM Company Info

Description

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It serves the life sciences research, clinical diagnostics, and drug discovery customers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.

Details
Name: Adaptive Biotechnologies Corporation
1HM
Exchange: DB
Founded: 2009
$3,290,061,946
126,317,893
Website: http://www.adaptivebiotech.com
Address: Adaptive Biotechnologies Corporation
1551 Eastlake Avenue East,
Suite 200,
Seattle,
Washington, 98102,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ADPT Common Stock Nasdaq Global Select US USD 27. Jun 2019
DB 1HM Common Stock Deutsche Boerse AG DE EUR 27. Jun 2019
MUN 1HM Common Stock Boerse Muenchen DE EUR 27. Jun 2019
Number of employees
Current staff
Staff numbers
453
Adaptive Biotechnologies employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/07 01:21
End of day share price update: 2020/04/06 00:00
Last estimates confirmation: 2020/04/06
Last earnings filing: 2020/02/26
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.